Publication | Closed Access
A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection
34
Citations
0
References
2017
Year
Surgical OncologyHepatic DisordersHepatologyOncologyViral HepatitisPhase Iii TrialHepatitisPathologyLiver CancerLiver TransplantationMedicineRadiation OncologyHepatocellular CarcinomaHepatitis Virus
No additional data available for this publication yet. Check back later!